Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics

(Difference between revisions)

Revision as of 17:31, 12 December 2010

DPP4 Inhibitor Pharmacokinetics
Parameter	Vildagliptin (Galvus)	Sitagliptin (Januvia)	Saxagliptin (Onglyza)
T_max (hr)	1.75	1-4	2
C_max (ng/ml)	Vildagliptin (Galvus)	Sitagliptin (Januvia)	Saxagliptin (Onglyza)
Bioavailability (%)	85	87	67
Protein Binding (%)	9	38	0
T_1/2 (hr)	2-3	12.4	2.5
AUC (ng/ml/hr)	Vildagliptin (Galvus)	Sitagliptin (Januvia)	Saxagliptin (Onglyza)
IC₅₀ (nM)	3	18	50
Renal Clearance (L/h)	13.0	21.0	13.8
Volume Distribution (L)	71	198	151
Dosage (mg)	100	100	5
Metabolism	Hydrolysis	Hepatic (CYP3A4 & CYP2C8)	Hepatic (CYP3A4)

For Pharmacokinetic Data References, see: References

@@ Line 21: / Line 21: @@
 ! 85
 ! 87
-! [67
+! 67
 |-
 ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
@@ Line 41: / Line 41: @@
 ! 3
 ! 18
-! [[Saxagliptin]]<br/>(Onglyza)
+! 50
 |-
 ! [[Pharmacokinetics#Clearance_.28Cl.29|Renal Clearance]] (L/h)
@@ Line 47: / Line 47: @@
 ! 21.0
 ! 13.8
+|-
+! Volume Distribution (L)
+! 71
+! 198
+! 151
 |-
 ! Dosage (mg)
@@ Line 54: / Line 59: @@
 |-
 ! Metabolism
-! [[Vildagliptin]]<br/>(Galvus)
+! Hydrolysis
-! [[Sitagliptin]]<br/>(Januvia)
+! Hepatic (CYP3A4 & CYP2C8)
-! [[Saxagliptin]]<br/>(Onglyza)
+! Hepatic (CYP3A4)
 |}
 For Pharmacokinetic Data References, see: [[Treatments:Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics|References]]